DESTIN, Fla. — Switching to a different drug class with a different mechanism of action can improve response in patients with difficult-to-treat rheumatoid arthritis, according to Janet Pope, MD, of Western University, in Ontario, Canada.
Pope made her comments, and expanded upon them in a presentation, at the Congress of Clinical Rheumatology East.
“This is not always the case, but in general, if someone is a secondary loss of response, say to a TNF inhibitor, or they stop it because of a side effect, or even a primary non-responder, in general I tend to move out of class,”